These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 21335209)

  • 1. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C.
    Durante-Mangoni E; Ragone E; Pinto D; Iossa D; Covino FE; Maiello C; Utili R
    Transplant Proc; 2011; 43(1):299-303. PubMed ID: 21335209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
    Sharma P; Marrero JA; Fontana RJ; Greenson JK; Conjeevaram H; Su GL; Askari F; Sullivan P; Lok AS
    Liver Transpl; 2007 Aug; 13(8):1100-8. PubMed ID: 17377914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Matthews AM; Fireman M; Zucker B; Sobel M; Hauser P
    Am J Psychiatry; 2006 Aug; 163(8):1342-7; quiz 1479. PubMed ID: 16877644
    [No Abstract]   [Full Text] [Related]  

  • 7. Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin?
    Donato MF; Agnelli F; Rigamonti C; Arosio E; Colombo M
    Liver Transpl; 2008 Sep; 14(9):1383-4; author reply 1385. PubMed ID: 18756490
    [No Abstract]   [Full Text] [Related]  

  • 8. Patterns of response during therapy with interferon and outcome of retreatment with interferon plus ribavirin for chronic hepatitis C.
    Ogana G; Tocco A; Garrucciu G; Branca B; Azara V; Manzoni NE; Deplano A; Solinas A
    J Clin Gastroenterol; 2001 Sep; 33(3):254-5. PubMed ID: 11500622
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin.
    Shrestha NK; Hamrock DJ
    Clin Infect Dis; 2010 Jul; 51(1):e4-6. PubMed ID: 20504235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy.
    Williams CN
    Can J Gastroenterol; 1997 Oct; 11(7):563-4. PubMed ID: 9395755
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone.
    Wright JJ; O'driscoll G
    J Heart Lung Transplant; 2005 Mar; 24(3):343-6. PubMed ID: 15737764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes.
    Craparo EF; Triolo D; Pitarresi G; Giammona G; Cavallaro G
    Biomacromolecules; 2013 Jun; 14(6):1838-49. PubMed ID: 23621358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.
    Kozlowski A; Harris JM
    J Control Release; 2001 May; 72(1-3):217-24. PubMed ID: 11390000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of interferon therapy on viral titers in patients with chronic hepatitis C who are positive for hepatitis GB virus C.
    Chayama K; Kobayashi M; Ikeda K; Kumada H
    J Hepatol; 1997 Oct; 27(4):769-70. PubMed ID: 9365058
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral use of interferon.
    Cummins JM; Beilharz MW; Krakowka S
    J Interferon Cytokine Res; 1999 Aug; 19(8):853-7. PubMed ID: 10476928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated Interferon Lambda for Covid-19.
    Wang M; Tang L; Huang L
    N Engl J Med; 2023 Jun; 388(22):2107-2108. PubMed ID: 37256989
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated Interferon Lambda for Covid-19.
    Andreakos E; Tsiodras S
    N Engl J Med; 2023 Jun; 388(22):2107. PubMed ID: 37256988
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegylated Interferon Lambda for Covid-19. Reply.
    Reis G; Mills EJ; Glenn JS
    N Engl J Med; 2023 Jun; 388(22):2108. PubMed ID: 37256990
    [No Abstract]   [Full Text] [Related]  

  • 19. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.
    Zuwala K; Riber CF; Løvschall KB; Andersen AHF; Sørensen L; Gajda P; Tolstrup M; Zelikin AN
    J Control Release; 2018 Apr; 275():53-66. PubMed ID: 29432822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical immunological effect of interferon in cases of influenza].
    Volkova LV; Vorob'eva NN; Bondarenko AL; Sedel'nikova NA; Okishev MA
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (6):50-3. PubMed ID: 18283734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.